You are in: eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Cardiology Atrioventricular Septal Defect, Partial and IntermediateArticle Last Updated: Sep 14, 2006AUTHOR AND EDITOR INFORMATIONAuthor: M Silvana Horenstein, MD, Associate in Pediatric and Fetal Cardiac Diagnostic, Diagnostico Gineco-Obstetrico, PC; Associate Director, Legacy Department, Best Doctors, Inc M Silvana Horenstein is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, and American Medical Association Coauthor(s): Michael A Portman, MD, Research Director, Department of Pediatrics, Division of Cardiology, Associate Professor, Childrens' Hospital Editors: Paul M Seib, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences; Medical Director, Cardiac Catheterization Laboratory, Co-Medical Director, Cardiovascular Intensive Care Unit, Arkansas Children's Hospital; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Alvin J Chin, MD, Professor of Pediatrics, Division of Cardiology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine; Gilbert Herzberg, MD, Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College; Steven R Neish, MD, SM, Director of Pediatric Cardiology Fellowship Program, Department of Pediatrics, Baylor College of Medicine Author and Editor Disclosure Synonyms and related keywords: AVSD, atrioventricular canal defect, mitral cleft, ostium primum defect, partial atrioventricular septal defect, partial common atrioventricular canal, endocardial cushion defects, intermediate atrioventricular septal defect, transitional common atrioventricular canal INTRODUCTIONBackgroundAtrioventricular septal defects (AVSDs), characterized by a deficiency of the atrioventricular septum, are a broad spectrum of malformations presumed to result from abnormal or inadequate fusion of the superior and inferior endocardial cushions with the mid portion of the atrial septum and the muscular (trabecular) portion of the ventricular septum. Several methods of classification and nomenclature exist, causing considerable confusion. The term partial AVSD (also called partial common atrioventricular canal) generally refers to endocardial cushion defects, which have an interatrial communication but lack an interventricular communication. In these types of defects the mitral and tricuspid annuli are separate. In addition, certain anatomic features should be present, alone or in combination: primum atrial septal defect (ASD), inlet ventricular septal defect (VSD), cleft of the anterior mitral valve leaflet, and wide anteroseptal tricuspid valve commissure or cleft septal tricuspid leaflet (See Image 1). The most frequently encountered abnormality in patients with partial AVSD is the combination of primum ASD and cleft of the anterior mitral valve leaflet. The term intermediate AVSD (also called transitional common atrioventricular canal) is variably defined; however, it most commonly refers to the combination of a partial AVSD with a small interventricular communication. This is an infrequent form of AVSD. There is usually a single valvar annulus where the anterior and posterior bridging leaflets fuse overlying the ventricular septum. Because of the leaflets' fusion there are two distinct valvar components (See Image 2). A thorough description of associated atrioventricular valve abnormalities should be included when classifying these defects. This article considers AVSDs that demonstrate minimal or no shunting through an interventricular communication. PathophysiologyIn the absence of obstruction of the right ventricular outflow tract, such as in pulmonary stenosis or pulmonary vascular obstructive disease, predominant left-to-right shunting occurs. The clinical presentation is determined by the degree of interatrial shunting, atrioventricular regurgitation, or both. The most inferior portion of the atrial septum is deficient. The resulting ostium primum defect varies in size and may occur in association with more superior ostium secundum–type ASDs. In some of the latter cases, only a small strand of the atrial septum remains, leading to the appearance of a common atrium. Some observers reserve the term common atrium for those cases with an additional sinus venosus deficiency. The degree of left-to-right shunting through the atrial defect is determined by the size of the communication and the relative compliance of the 2 atria and ventricles. Ventricular compliance is affected by the level of pulmonary vascular resistance (PVR). In the newborn with a less compliant right ventricle (RV) and relatively high PVR, little left-to-right shunting occurs. If the defect is extremely large, obligatory mixing in a common, or near-common, atrium creates a component of right-to-left shunting. Left-to-right shunting increases with age as PVR decreases and RV compliance increases. This results in progressive RV enlargement and pulmonary vascular engorgement. The atrioventricular valves are abnormal, even in a partial AVSD. Fusion failure of the endocardial cushions usually results in a separation or cleft in the anterior mitral valve leaflet. The degree of regurgitation through the cleft depends on its size and, occasionally, on the coexistence of left ventricular outflow tract (LVOT) obstruction or coarctation of the aorta. Typically, the cleft directs regurgitant blood through the atrial defect, creating an LV-to-RA (right atrium) shunt. RA enlargement, rather than left atrial (LA) enlargement, may occur. In addition, mitral regurgitation (MR) contributes to LA and LV enlargement. FrequencyUnited StatesPrevalence estimates of cardiovascular malformations in large cohorts vary from 4-8 per 1000 births. AVSD constitutes 5-8% of these defects. Incidence of AVSD in fetuses is 17%; however, occurrence of partial AVSD has not been separated from this general classification. Studies report the incidence of congenital heart defect (CHD) in children with Down syndrome (trisomy 21) to be 42-48%. Of those CHDs, 45% are AVSDs. In general, AVSDs, when not associated with heterotaxia syndrome, occur commonly in Down syndrome. Partial AVSD, as opposed to complete AVSD, of the ostium primum type is more common in patients without Down syndrome. InternationalInternational frequency of cardiovascular malformations is similar to US figures. Mortality/MorbidityLeft-to-right shunting through the atrial communication is generally well tolerated through the first decade of life. Patients are asymptomatic if MR is mild or absent. Symptoms of left-to-right shunting may develop in adolescence and are exacerbated by atrial arrhythmia. Sinus node dysfunction may occur and contributes to exercise intolerance if the defect is not repaired. Moderate to severe MR may lead to morbidity in infancy and early childhood. Severe MR causes congestive heart failure (CHF) and failure to thrive in infants; it may result in death if left untreated. A large left-to-right shunt from the LV to the RA through a cleft mitral valve causes volume overload in both ventricles, with CHF early in life. CLINICALHistoryIn the absence of moderate to severe MR and other associated CHD, partial AVSD is often discovered later in childhood when the patient is referred for evaluation of a heart murmur. Also, partial AVSD is less common in Down syndrome than in complete AVSD.
Physical
CausesFor CHD, experimental and epidemiologic data suggest that a single mechanism may cause a range of anatomic malformations. Specifically, AVSDs are presumed to occur secondary to extracellular matrix abnormalities that produce faulty development of the endocardial cushions and the atrioventricular septum. Normal development of the human heart requires an orderly coordination of transcriptional programs. One of the most important factors for the differentiation of mesodermal progenitor cells is the homeobox protein Nkx-2.5. For example, the lack of Nkx-2.5 in mice arrests heart development prior to looping, which is lethal. In humans, 28 germline Nkx-2.5 mutations have been associated with CHD. Recent studies have shown that mutations in the gene Nkx-2.5 are associated specifically with AVSD and VSD. DIFFERENTIALSAtrial Septal Defect, Coronary Sinus Atrial Septal Defect, Ostium Secundum Atrial Septal Defect, Sinus Venosus Mitral Valve Insufficiency Mitral Valve Prolapse Partial Anomalous Pulmonary Venous Connection
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Enalapril (Vasotec) |
|---|---|
| Description | Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in increased levels of plasma renin and a reduction in aldosterone secretion. Helps control blood pressure and proteinuria. Decreases pulmonary-to-systemic flow ratio in the catheterization laboratory and increases systemic blood flow in patients with relatively low pulmonary vascular resistance. Has favorable clinical effect when administered over a long period. Helps prevent potassium loss in distal tubules. Body conserves potassium; thus, less oral potassium supplementation needed. Patients who develop a cough, angioedema, bronchospasm, or other hypersensitivity reactions after starting ACE inhibitors should receive an angiotensin-receptor blocker. |
| Adult Dose | 2.5-5 mg/d PO; increase prn Dosing range: 10-40 mg/d PO qd or divided bid Alternatively, 1.25 mg/dose IV over 5 min q6h |
| Pediatric Dose | 0.1-0.5 mg/kg/d PO qd or divided bid. Doses as high as 1 mg/kg/d have been reported to be well tolerated. |
| Contraindications | Documented hypersensitivity |
| Interactions | NSAIDs may reduce hypotensive effects of enalapril; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases enalapril levels; probenecid may increase enalapril levels; the hypotensive effects of ACE inhibitors may be enhanced when given concurrently with diuretics. |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Pregnancy category D in second and third trimesters; caution in renal impairment, valvular stenosis, or severe congestive heart failure. |
| Drug Name | Captopril (Capoten) |
|---|---|
| Description | Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion. Rapidly absorbed, but bioavailability is significantly reduced with food intake. It achieves a peak concentration in an hour and has a short half-life. The drug is cleared by the kidney. Impaired renal function requires reduction of dosage. Absorbed well PO. Give at least 1 h before meals. If added to water, use within 15 min. Can be started at low dose and titrated upward as needed and as patient tolerates. |
| Adult Dose | 6.25-25 mg PO bid/tid; increase dose by 25 mg prn at 1- to 2-wk intervals; not to exceed 450 mg/d divided tid Clcr 10-50 mL/min: give 75% of starting dose Clcr <10 mL/min: give 50% of starting dose |
| Pediatric Dose | Neonates: 0.05-0.1 mg/kg/dose PO q6-24h; titrate dose up to 0.5 mg/kg/dose prn Infants: 0.15-0.3 mg/kg/dose PO q6-24h; titrate dose up; not to exceed 6 mg/kg/d in 2-4 divided doses prn Children: 0.3-0.5 mg/kg/dose PO q6-24h; titrate dose up; not to exceed 6 mg/kg/d in 2-4 divided doses prn |
| Contraindications | Documented hypersensitivity; renal impairment |
| Interactions | NSAIDs may reduce hypotensive effects of captopril; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases captopril levels; probenecid may increase captopril levels; the hypotensive effects of ACE inhibitors may be enhanced when given concurrently with diuretics |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Pregnancy category D in second and third trimesters; caution in renal impairment, valvular stenosis, or severe congestive heart failure |
| Drug Name | Lisinopril (Prinivil, Zestril) |
|---|---|
| Description | Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion. |
| Adult Dose | 10 mg/d PO; increase 5-10 mg/d at 1-2 wk intervals; not to exceed 40 mg |
| Pediatric Dose | Not established, data limited; 0.2 mg/kg PO qd initially; increase as BP and symptoms (eg, dizziness, light-headedness) allow |
| Contraindications | Documented hypersensitivity |
| Interactions | NSAIDs may reduce hypotensive effects of lisinopril; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases lisinopril levels; probenecid may increase lisinopril levels; the hypotensive effects of ACE inhibitors may be enhanced when given concurrently with diuretics |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Pregnancy category D in second and third trimesters; caution in renal impairment, valvular stenosis, or severe congestive heart failure |
These agents help decrease pulmonary congestion.
| Drug Name | Furosemide (Lasix) |
|---|---|
| Description | Loop diuretic that increases excretion of water by interfering with chloride-binding cotransport system, which in turn inhibits sodium and chloride reabsorption in ascending limb of loop of Henle and distal renal tubule. Increases renal blood flow without increasing filtration rate. Onset of action generally is within 1 h. Increases potassium, sodium, calcium, and magnesium excretion. Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate with 1 mg/kg/dose increments until a satisfactory effect is achieved. Diuretics have major clinical uses in managing disorders involving abnormal fluid retention (edema) or in treating hypertension, in which their diuretic action causes decreased blood volume. Chronic use of furosemide can lead to hypercalcemia with renal damage and electrolyte disturbances. |
| Adult Dose | 20-80 mg/d PO/IV/IM; titrate up to 600 mg/d for severe edematous states |
| Pediatric Dose | 1-2 mg/kg/dose PO; not to exceed 6 mg/kg/dose; do not administer more frequently than q6h Alternatively, 1 mg/kg IV/IM slowly under close supervision; not to exceed 6 mg/kg |
| Contraindications | Documented hypersensitivity; hepatic coma, anuria, and state of severe electrolyte depletion |
| Interactions | Metformin decreases furosemide concentrations; furosemide interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides and furosemide; hearing loss of varying degrees may occur; anticoagulant activity of warfarin may be enhanced when taken concurrently with this medication; increased plasma lithium levels and toxicity are possible when taken concurrently with this medication |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Perform frequent serum electrolyte, CO2, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter |
| Drug Name | Spironolactone (Aldactone) |
|---|---|
| Description | For management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions. Therefore, it is generally used when there is concomitant chronic use of sodium-wasting diuretics such as furosemide. |
| Adult Dose | 25-200 mg/d PO in 1-2 divided doses |
| Pediatric Dose | Maintenance: 1 mg/kg/dose PO up to qid |
| Contraindications | Documented hypersensitivity; anuria, renal failure or hyperkalemia |
| Interactions | May decrease effect of anticoagulants; potassium and potassium-sparing diuretics may increase toxicity of spironolactone |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in renal and hepatic impairment |
It is used because of its direct inotropic effects in addition to indirect effects on the cardiovascular system.
Its indirect actions result in increased carotid sinus activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure. These effects help reduce the heart rate response to CHF, rendering a more effective stroke volume with each ventricular systole.
| Drug Name | Digoxin (Lanoxin) |
|---|---|
| Description | Enhances myocardial contractility by inhibition of Na+/K+ ATPase, a cell membrane enzyme that extrudes Na and brings K into the myocyte. Resulting increase in intracellular Na stimulates Na-Ca exchanger in the cell membrane, which extrudes Na and brings in Ca, leading to an increase in intracellular calcium in the sarcoplasmic reticulum of cardiac cells, therefore increasing contractility of myocyte (ie, positive inotropic effect). Has direct inotropic effects in addition to indirect effects on the cardiovascular system. Increases myocardial systolic contractions. It exerts vagomimetic action on sinus and AV nodes (slowing heart rate and conduction). Also, decreases degree of activation of sympathetic nervous system and renin-angiotensin system, which is referred to as the deactivating effect. May be given as a loading dose followed by a maintenance dose or simply as a maintenance regimen. Digitalis loading increases hazards of this drug. Therapeutic serum level range is 0.8-2 ng/mL. |
| Adult Dose | 0.125-0.5 mg PO qd |
| Pediatric Dose | Premature infants: 0.005-0.0075 mg/kg if tablet; 0.004-0.006 mg/kg if capsule, IV, or IM divided q12h Full-term infants: 0.006-0.010 mg/kg if tablet; 0.005-0.008 if capsule, IV, or IM divided q12h 1-24 months: 0.010-0.015 mg/kg if tablet; 0.0075-0.012 mg/kg if capsule, IV, or IM divided q12h 2-5 years: 0.0075-0.010 mg/kg if tablet; 0.006-0.009 mg/kg if capsule, IV, or IM divided q12h 5-10 years: 0.005-0.010 mg/kg if tablet; 0.004-0.008 mg/kg if capsule, IV, or IM divided q12h >10 years: 0.0025-0.005 mg/kg if tablet; 0.002-0.003 if capsule, IV, or IM qd or divided q12h |
| Contraindications | Documented hypersensitivity; beriberi heart disease, idiopathic hypertrophic subaortic stenosis, constrictive pericarditis, and carotid sinus syndrome |
| Interactions | IV calcium may produce arrhythmias in digitalized patients; medications that may increase digoxin levels include alprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, oral amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil Medications that may decrease serum digoxin levels include aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, oral colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic acid |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Hypokalemia may reduce positive inotropic effect of digitalis; hypercalcemia predisposes patient to digitalis toxicity, and hypocalcemia can make digoxin ineffective until serum calcium levels are normal; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients diagnosed with incomplete A-V block may progress to complete block when treated with digoxin; exercise caution in hypothyroidism, hypoxia, and acute myocarditis; adjust dose in renal impairment; highly toxic (overdoses can be fatal) |
| Media file 1: Partial atrioventricular septal defect (AVSD): The mitral and tricuspid annuli are separate.The cleft in the mitral leaflet is in the anterior position. This type of anatomy is usually associated with a primum atrial septal defect (ASD). Partial AVSD is more common than intermediate AVSD. | |
![]() | View Full Size Image | Media type: Image |
| Media file 2: Intermediate atrioventricular septal defect (AVSD): There is a single valve annulus. The anterior and posterior bridging leaflets are fused (whereas in complete AVSD the anterior and posterior bridging leaflets are not fused). Therefore, the atrioventricular valve has a tricuspid and a mitral component. Intermediate AVSD is the least common type of AVSD. | |
![]() | View Full Size Image | Media type: Image |
| Media file 3: Echocardiogram of the apical 4-chamber view demonstrating a partial atrioventricular septal defect (AVSD). Chambers are denoted by RA, right atrium; RV, right ventricle; and LV, left ventricle. | |
![]() | View Full Size Image | Media type: Image |
| Media file 4: Echocardiogram with subcostal view demonstrates an atrioventricular septal defect (AVSD). A portion of the ostium secundum atrial septum is also missing, just superior to the ostium primum defect. | |
![]() | View Full Size Image | Media type: Image |
| Media file 5: Color Doppler demonstrates left-to-right shunting through the partial atrioventricular septal defect (AVSD) shown in Images 1-2. | |
![]() | View Full Size Image | Media type: Image |
| Media file 6: Left superior axis deviation in the frontal plane and rR' pattern in right precordial leads. | |
![]() | View Full Size Image | Media type: ECG |
Atrioventricular Septal Defect, Partial and Intermediate excerpt
Article Last Updated: Sep 14, 2006